⚠️Mark your calendar for the Dr. GPCR Summit 2022 held between Oct. 10 - 16, it's FREE!

September 2022 "Introduction Protease activated receptors 1 (PAR1) and 4 (PAR4) agonists are used to Here we show that C1INH affects platelet activation through PAR1 and PAR4 agonists. The platelet suspensions were exposed to PAR1 agonists SFLLRN, TFLLR and TFLLRN; PAR4 agonists AYPGKF

October 2022 "Protease-activated receptor 2 (PAR2) is a G-protein-coupled receptor (GPCR) activated by of PAR2 that induces unique cellular signaling, distinct from trypsin and PAR2-activating peptide (AP Interestingly, unlike PAR2-AP, GB83 and trypsin induced sustained receptor endocytosis and PAR2 colocalization by GB83, which may be the reason why GB83 is recognized as an antagonist of PAR2. Our results revealed that GB83 is a bona fide agonist of PAR2 that uniquely modulates PAR2-mediated cellular

However, it has become evident that heterotrimeric G-proteins can also be activated via GPCR-independent By revealing that small molecules can selectively disable noncanonical mechanisms of G-protein activation Zhao , Vincent DiGiacomo , Mariola Ferreras-Gutierrez , Shiva Dastjerdi , Alain Ibáñez de Opakua , Jong-Chan Park , Alex Luebbers , Qingyan Chen , Aaron Beeler , Francisco J Blanco , Mikel Garcia-Marcos .

demonstrate its ability to promote cancer cell motility. " Authors Yu Jin Lee , Kyeong Jin Shin , Hyun-Jun Jang , Jin-Sun Ryu , Chae Young Lee , Jong Hyuk Yoon , Jeong Kon Seo , Sabin Park , Semin Lee , A Reum Je , Yang Hoon Huh , Sun-Young Kong , Taejoon Kwon , Pann-Ghill Suh , Young Chan Chae Tags GPR143 , HRS

Authors Jong Min Hong , Jin-Woo Lee , Dong-Seung Seen , Jae-Yeon Jeong , Won-Ki Huh Tags Cancer , Chemokine